MergerAug 11, 2026, 04:38 PM
SYNLOGIC to Merge with Caldera Therapeutics
AI Summary
SYNLOGIC, INC. announced a definitive Merger Agreement with Caldera Therapeutics, Inc., which will result in the formation of Sonic Holdco, Inc., with the combined entity operating as Caldera Therapeutics. This strategic move follows Synlogic's decision to discontinue its lead clinical program and undergo a corporate restructuring. Existing Synlogic shareholders are projected to own approximately 2.3% of the combined company, reflecting a significant pivot for the biopharmaceutical firm. The company reported a net loss of $(0.543) million for the second quarter of 2026, but a net income of $0.138 million for the first half of 2026, largely due to a change in fair value of warrant liability.
Key Highlights
- SYNLOGIC, INC. entered a Merger Agreement with Caldera Therapeutics, Inc. to form Sonic Holdco, Inc.
- The combined company will operate as Caldera Therapeutics, focusing on CLD-423 for inflammatory bowel disease.
- Pre-merger Synlogic security holders are expected to own approximately 2.3% of the combined company.
- Synlogic was valued at $18.0 million for the merger, assuming $6.0 million net cash.
- Caldera was valued at $500.0 million for the merger, with a concurrent financing of $278.0 million.
- Net loss for Q2 2026 was $(0.543) million, compared to a net income of $0.138 million for H1 2026.
- Cash and cash equivalents stood at $13.183 million as of June 30, 2026.
- The exercise price of purchase warrants was reduced to $0.70 per share on July 27, 2026.
Price Impact
More from SYBX